Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 1500
Single User License Price INR 103500
Corporate User License Price USD 4500
Corporate User License Price INR 310500
Site License Price USD 3000
Site License Price INR 207000
Request a Quote

Report Title

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016

Quote Request for License Type
License Type Price  
Single User License USD 1500
Site License USD 3000
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016


Quote Request for License Type
License Type Price  
Single User License USD 1500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016



Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q4 2016", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q4 2016 with 986 deals worth USD81.7 billion, as compared 1,194 worth USD85.9 billion in Q4 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q4 2016, when compared to 1,009 deals worth USD112.6 billion in Q3 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD1 billion in Q4 2016, as compared USD1.6 billion in Q4 2015. On a quarter-on-quarter basis, the upfront payments reported an increase in Q4 2016, when compared to USD589.2m in Q3 2016. Deals in oncology therapeutics market registered an increase with 339 deals in Q4 2016, compared to 330 deals in Q3 2016. North America registered a decrease in the number of deals with 630 deals in Q4 2016, compared to 690 deals in Q3 2016.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2016 11

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2016 11

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2016 13

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2016 14

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2016 15

2.4.1 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 15

2.4.2 Pfizer Raises USD6 Billion in Public Offering of Notes 15

2.4.3 Lonza to Acquire Capsugel from KKR & Co for USD5.5 Billion 16

2.4.4 Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 16

2.4.5 Nanjing Hicin Pharma to Raise USD3.19 Billion in IPO of Shares 17

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 18

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2016 18

3.1.1 Top M&A Deals in Q4 2016 19

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2015-Q4 2016 20

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2016 21

3.2.1 Top Initial Public Offerings in Q4 2016 22

3.2.2 Top Secondary Offerings in Q4 2016 22

3.2.3 Top PIPE Deals in Q4 2016 23

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2015-Q4 2016 24

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2016 25

3.3.1 Top Venture Financing Deals in Q4 2016 26

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2016 27

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2016 27

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2015-Q4 2016 29

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2015-Q4 2016 30

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2015-Q4 2016 31

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2016 32

3.4.1 Top Private Equity Deals in Q4 2016 33

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2015-Q4 2016 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2016 35

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2016 35

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2015-Q4 2016 36

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 37

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2016 38

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2016 38

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2016 39

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 40

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2015-Q4 2016 41

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2015-Q4 2016 42

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 43

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2016 45

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2016 45

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 46

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2016 47

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2016 48

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2016 49

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2015-Q4 2016 50

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2015-Q4 2016 51

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2015-Q4 2016 52

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2015-Q4 2016 53

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2015-Q4 2016 55

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 57

6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2015-Q4 2016 57

6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2015-Q4 2016 58

6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2015-Q4 2016 59

6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2015-Q4 2016 60

6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2015-Q4 2016 61

6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2015-Q4 2016 62

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2016 63

7.1.1 Oncology-Deals of the Quarter 64

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2016 67

7.2.1 Central Nervous System-Deals of the Quarter 68

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2016 70

7.3.1 Infectious Disease-Deals of the Quarter 71

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2016 73

7.4.1 Immunology-Deals of the Quarter 74

7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2016 76

7.5.1 Metabolic Disorders-Deals of the Quarter 77

7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2016 79

7.6.1 Cardiovascular-Deals of the Quarter 80

7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2016 81

7.7.1 Gastrointestinal-Deals of the Quarter 82

7.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q4 2016 84

7.8.1 Hematological Disorders-Deals of the Quarter 85

7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2016 88

7.9.1 Respiratory-Deals of the Quarter 89

7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2016 91

7.10.1 Dermatology-Deals of the Quarter 92

8 Deal Summary by Geography 94

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2016 94

8.1.1 North America-Deals of the Quarter 95

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2016 97

8.2.1 Europe-Deals of the Quarter 98

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2016 100

8.3.1 Asia-Pacific-Deals of the Quarter 101

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2016 103

8.4.1 Rest of the World-Deals of the Quarter 104

9 Pharmaceuticals & Healthcare, Global, Top Advisors 106

9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2015-Q4 2016 106

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2015-Q4 2016 107

10 Appendix 108

11 Further Information 109

11.1 Methodology 109

11.2 About GlobalData 110

11.3 Contact Us 110

11.4 Disclosure information 111

11.5 Disclaimer 111

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 11

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2016 13

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2016 14

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 18

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2015-Q4 2016 20

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 21

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2015-Q4 2016 24

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 25

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2016 27

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2016 27

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2015-Q4 2016 29

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 30

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 32

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2015-Q4 2016 33

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 35

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 36

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 37

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 40

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015-Q4 2016 41

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015-Q4 2016 42

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 43

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 45

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 46

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 50

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 51

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2015-Q4 2016 52

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2015-Q4 2016 53

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 55

Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2015-Q4 2016 57

Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2015-Q4 2016 58

Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2015-Q4 2016 59

Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2015-Q4 2016 60

Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2015-Q4 2016 61

Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2015-Q4 2016 62

Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 63

Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 67

Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 70

Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 73

Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 76

Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 79

Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 81

Figure 42: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 84

Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 88

Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 91

Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 94

Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 97

Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 100

Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 103

Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 106

Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 107

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 12

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2016 14

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2016 15

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 19

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2016 19

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2015-Q4 2016 20

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 22

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2016 22

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2016 22

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2016 23

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 24

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 25

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2016 26

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2016 28

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 29

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 30

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2015-Q4 2016 31

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 32

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2016 33

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2015-Q4 2016 34

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 35

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 36

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 37

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 38

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2016 38

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2016 39

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 40

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015-Q4 2016 42

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 44

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 45

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015-Q4 2016 46

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2016 47

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2016 48

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2016 49

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 50

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2015-Q4 2016 51

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015-Q4 2016 54

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2015-Q4 2016 56

Table 39: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2015-Q4 2016 57

Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2015-Q4 2016 58

Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2015-Q4 2016 59

Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2015-Q4 2016 60

Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2015-Q4 2016 61

Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2015-Q4 2016 62

Table 45: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 64

Table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 68

Table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 71

Table 48: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 74

Table 49: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 77

Table 50: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 80

Table 51: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 82

Table 52: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 85

Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 89

Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 92

Table 55: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 95

Table 56: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 98

Table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 101

Table 58: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 104

Table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 106

Table 60: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2015-Q4 2016 107

Table 61: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q4 2015-Q4 2016 108

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person